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Background 
In clinical trials the use of inhaled corticosteroids is associated with an increased risk of pneumonia in 
people with chronic obstructive pulmonary disease but whether the same is true for people with asthma is 
not known. 
 
Methods 
Using primary care data from The Health Improvement Network we identified people with asthma and 
from this cohort we identified cases with pneumonia/ lower respiratory tract infection, and age and sex 
matched controls. Conditional logistic regression was used to determine the association between the 
dose and type of inhaled corticosteroid and risk of pneumonia or LRTI.    
 
Results 
There was a dose response relationship between strength of dose of inhaled corticosteroid and risk of 
pneumonia or lower respiratory tract infection (p-trend <0∙001), such that after adjusting for confounders 
people receiving the highest strength of inhaled corticosteroid (≥1000mcg) had a 1.85 (95% CI 1∙56 to 
2∙19) increased risk of pneumonia or lower respiratory infection when compared to people with asthma 
who did not have a prescription for inhaled corticosteroids within the previous 90 days.  
 
Conclusion 
People with asthma receiving inhaled corticosteroids are at an increased risk of pneumonia or lower 
respiratory infection with people receiving higher doses at greater risk. Pneumonia should be considered 
as a possible side effect of inhaled corticosteroids and the lowest dose of inhaled corticosteroids possible 
should be used in the management of asthma.  
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Background  
Inhaled corticosteroids (ICS) are prescribed widely to people with asthma (1) and chronic obstructive 
pulmonary disease (COPD) (2) to improve symptoms, maximise lung function and reduce exacerbation 
risk. Recent evidence suggests that ICS may be associated with an increased risk of pneumonia in 
people with COPD (3-5). 
Although asthma is an independent risk factor for invasive pneumococcal disease (6) it is not known 
whether ICS are independently associated with an increased risk of pneumonia in people with asthma. 
We set out to examine whether ICS are associated with an increased risk of pneumonia or lower 
respiratory tract infection (LRTI) in people with asthma by using computerised primary care data and a 
matched case-control design. 
 
Methods  
We extracted data from the Health Improvement Network (THIN: www.thin-uk.com) database. This 
database contains electronic medical records of 9∙1 million patients collected from over 479 general 
practices in the U.K.  We identified a cohort of people with a recorded diagnosis of asthma after 1/4/2004, 
aged between 18 and 80. We performed a nested case control study in this cohort; cases were defined 
by first recorded diagnosis of pneumonia or LRTI using previously defined Read codes for pneumonia (7).  
The date of the diagnosis of pneumonia/LRTI was considered the index date. Six controls per case were 
matched to cases based on sex, and age at index date (within three years) from the remaining population 
of people with asthma. Ethics approval to use data from THIN (The Health Improvement Network) was 
given by the NHS South-East Multi-centre Research Ethics Committee for studies using pre-collected, 
anonymised data (Ref number 07/H1102/103). 
Our main hypothesis was that the risk of pneumonia/LRTI would be associated with the current use of 
ICS and for this reason we initially identified all prescriptions for ICS up to 90 days before the index date.  
In the UK the average duration of a prescription can be up to 90 days. We grouped our ICS according to 
type into beclometasone dipropionate, fluticasone propionate, budesonide and a combined group of 
ciclesonide and mometasone furoate. The latter two were combined due to low numbers. Where the type 
of inhaled corticosteroid was changed in the previous 90 days we defined exposure according to the last 
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prescription. We excluded individuals who were prescribed more than one type of inhaled corticosteroid 
inhaler on the same day (n=78).   
To define the dose of inhaled corticosteroid we used the dose of drug delivered with each inhalation as 
information on puffs prescribed per day is recorded inconsistently in primary care datasets. To allow for 
different dose equivalence between drugs budesonide was considered equivalent to beclomethasone and 
a dose multiplying factor of 2 for fluticasone propionate was used.  For each drug type we defined a high 
and a low dose based on a cut-point of 200 mcg except for fluticasone where we used a cut point of 250 
mcg.  These cut points represent the step at which a long acting β2 agonist is introduced in the U.K. 
asthma guidelines (1). 
Our a priori confounders were smoking status (most recent recording) and co-morbidity as defined by the 
use of the Charlson Comorbidity Index score (8). Other potential confounders considered were influenza 
vaccination in the previous year; number of courses of reliever inhalers in the year previous year, both 
total, and separated by short acting β2 agonists and long acting β2 agonists; effect of oral corticosteroids 
(number of courses in the year prior to the index date), and Townsend socio-economic status score.  
We estimated the association between inhaled corticosteroid use and pneumonia/ LRTI by using 
conditional logistic regression and various different exposures including, in a step wise fashion, type of 
inhaled corticosteroid, dose of inhaled corticosteroid and then a combination of type of dose of inhaled 
corticosteroid. We then adjusted our models for a priori confounders and included other confounders if 
they altered the odds ratios for the exposure/outcome association by more than 10%.  
We performed a number of sensitivity analyses to determine if the effect was similar in different patient 
populations and examined whether the effect was similar for diagnosis of pneumonia versus LRTI.  We 
examined the data after excluding those with diagnosis of bronchiectasis and COPD.  We also examined 
the data only in those individuals who had not changed the type of inhaler in the previous 90 days, and 
included the number of short acting and long acting inhalers in the last year separately in the model.  All 
analyses were completed in Stata 11 (College Station, Texas).   
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Results 
We identified 9059 people with asthma and pneumonia or LRTI and 54189 age and sex matched 
controls, from a cohort of 359172 people with asthma (Table 1).  The mean age of the population was 
58∙6 years with a range from 18 to 87.  People with asthma and pneumonia/LRTI (cases) were more 
likely to smoke, had a higher Charlson index (i.e. more comorbid illness), and were from a lower social 
class as compared to controls (Table 1).  People with asthma and pneumonia/LRTI were also more likely 
to have a co-existent diagnosis of COPD, to have received a flu vaccination in the previous year (Table 
1), used more reliever inhalers and had more prescriptions for oral steroids in the previous year, when 
compared to controls (Table 2).   
People with asthma and pneumonia/LRTI were more likely to have a prescription for ICS in the last 90 
days than their matched controls (Table 2).  After adjusting for confounders the odds ratio for this 
association was 1∙2 (95% CI 1∙12 to 1∙27) (Table 3).   
 
Steroid Type 
We examined the risk of pneumonia/LRTI by inhaled corticosteroid type. After adjusting for confounders, 
budesonide use demonstrated a small increased risk (on the borderline of statistical significance) for 
pneumonia/LRTI (OR 1∙10, 95% 1∙00 to 1∙21, p=0∙057).  There was a higher risk of pneumonia/LRTI in 
individuals receiving fluticasone propionate (OR 1∙48 95% CI 1∙37 to 1∙59, p<0∙001).  None of the 
remaining steroid inhalers were associated with evidence of an increased risk (Table 3). 
For fluticasone propionate the results were consistent if the 490 individuals who changed their steroid 
inhaler in the previous 90 days were excluded. The results were also similar when the cases were 
separated on a diagnosis of LRTI or pneumonia; the odds ratio for fluticasone propionate use and risk of 
LRTI (n = 4666) was 1∙57 (95% CI 1∙41 to 1∙75); for pneumonia (n=4392) the odds ratio was 1∙42 (95% 
CI 1∙27 to 1∙58).  The results were consistent when individuals with bronchiectasis were excluded, when 
the number of short acting and long acting reliever inhalers were included separately in the model and 
also when individuals with COPD were excluded from the analyses. 
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For budesonide the size of effect tended to be similar through the analyses, however the significance 
varied. The following sensitivity analyses produced a significant effect; firstly when individuals with COPD 
were excluded from the study population (OR for budesonide and risk of pneumonia/LRTI 1∙17 95% CI 
1∙04 to 1∙32) and when the case population was restricted to those with pneumonia alone (OR for 
budesonide 1∙72 95% CI 1∙37 to 2∙17). 
 
Steroid Dose 
2∙9% of the asthmatics with pneumonia/LRTI were prescribed the highest does of inhaled corticosteroid 
(≥1000mcg), as compared to only 1% in the control population (p<0∙001). There was a dose response 
relationship between strength of ICS and infection risk (p-trend = p<0∙001) such that after adjusting for 
confounders, individuals on the highest dose of inhaled corticosteroid (≥1000mcg) were 1∙85 (95% CI 
1∙56 to 2∙19) times more likely to have a pneumonia/LRTI. (Table 3).  
These results remained consistent in the various sensitivity analyses and after excluding the 490 cases 
with a change of inhaler in the previous 90 days (OR for steroid dose ≥1000mcg 1∙82 95% CI 1∙53 to 
2∙16, p-trend <0∙001).  When separating the cases into pneumonia or LRTI the effect was stronger for 
pneumonia; for the highest dose of inhaled corticosteroid (≥1000mcg) the odds ratio was 2∙06 (95% CI 
1∙61 to 2∙65, p-trend p<0∙001) for pneumonia (n= 4393) when compared to an odds ratio of 1∙72 (95% CI 
1∙37 to 2∙17) for LRTI (n= 4666), (p-trend <0∙001).  
In addition, the results for the highest level of ICS were similar if individuals with concomitant COPD were 
excluded; the odds ratio for people with asthma and pneumonia/LRTI receiving ≥1000mcg was 2.05 
(95% CI 1∙59 to 2∙64 p-trend <0∙001).  
 
 
Steroid dose and type combined  
There was a significantly increased risk of pneumonia/LRTI in people with asthma with beclometasone 
and fluticasone at higher dose (>200mcg), but only fluticasone at lower dose (Table 4).  The various 
sensitivity analyses had similar results.   
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To try and control for asthma severity as a confounder we lastly restricted our analyses to people only 
receiving ICS; we used people receiving low dose beclometasone as our baseline group. Using this 
restricted dataset in the adjusted analyses we found the following; individuals prescribed high dose 
beclometasone group were 23% more likely to have a pneumonia/LRTI episode (OR 1∙23 95% CI 1∙00 to 
1∙53). Prescriptions of low and high dose budesonide and low and high dose fluticasone increased the 
risk of infection with the largest effect found for people prescribed high dose fluticasone with a 78% (OR 
1∙78 95% CI 1∙19 to 1∙83) increased risk of having pneumonia/LRTI as compared to those individuals 
prescribed low dose beclometasone (Table 5).   
 
Discussion 
To our knowledge this is the first study to demonstrate a relationship between inhaled corticosteroid use 
by type and dose and an increased risk of pneumonia or LRTI in asthma. In our study people with asthma 
and pneumonia or LRTI were more likely to be receiving high dose ICS. These results were consistent for 
both a diagnosis of LRTI and for pneumonia and were also similar after a number of different sensitivity 
analyses, including controlling for asthma severity. The results remained consistent when restricted to 
people under the age of 40 negating any confounding effect of COPD.  There was a clear dose response 
relationship with higher prescribed doses of inhaled corticosteroid being associated with a higher risk of 
infection. The only ICS associated with an increased risk of LRTI or pneumonia across all analyses was 
fluticasone proprionate. 
A major strength of this study population is its size. Our study is the largest to date with 9059 cases of 
pneumonia or LRTI identified. The associations described remained consistent after a number of 
sensitivity analyses including examining the effect in different age populations, and when excluding a 
recorded diagnosis of COPD.  
Using data from primary care records has limitations; we cannot confirm compliance with inhaled 
corticosteroid use and we cannot assess device type. Furthermore individuals may be using a drug that 
was prescribed previous to the 90 day index period however this misclassification would bias the results 
towards the null hypothesis.  Our study also suffers from a similar limitation to the studies of pneumonia in 
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COPD, namely that a diagnosis of pneumonia was not confirmed radiographically, however the diagnosis 
of pneumonia and lower respiratory infection has been previously shown to be reasonably accurate (7). 
Lower lung function (9) is known to be associated with an increased risk of pneumonia with more severe 
asthma and lower lung function carrying the highest risk, however the increased risk of pneumonia or 
LRTI remained despite correction for age, smoking status and Charlson index, reducing the effect of 
these limitations. We also corrected for the number of oral steroids prescribed in the last year, which is 
associated with both disease severity and decline in lung function (10), and for use of reliever inhalers 
which is associated with an increased risk of an adverse asthma outcome (11). 
As asthma severity is an independent risk factor for pneumonia (6, 12) we attempted to control for asthma 
severity as a confounder by restricting our analysis. We used low dose beclometasone as our baseline 
and analysed only those people who received ICS. This did not substantially change the results and the 
dose response trend remained unaffected, however we acknowledge that it is impossible to fully remove 
severity as a confounder. 
The possibility that ICS may be associated with an increased risk of pneumonia in obstructive lung 
disease followed the results of the TORCH (Towards a Revolution in COPD Health) study (5) which study 
examined the potential benefit of fluticasone propionate and salmeterol on mortality in COPD. The study 
reported a 19% 3 year rate of pneumonia in patients receiving fluticasone at ≥1000mcg/day 
corresponding to a significant 1∙6 fold increase over placebo.  
There have few studies in asthma. A meta-analysis from O’Byrne and colleagues assessed the risk of 
pneumonia in a retrospective analysis of budesonide use in asthma. The primary data set were all 
double-blind, placebo controlled trials lasting at least 3 months, involving budesonide (26 trials, n= 9067 
for budesonide; n=5926 for the comparator) with 62 cases of pneumonia reported as either an adverse, or 
serious adverse event for budesonide, and 82 for the comparator. In the primary data set the rate of 
pneumonia adverse events was 0∙5% (rate 10/1000 patient years) for budesonide and 1∙2% (19∙3/1000 
patient years) for placebo. The occurrence of pneumonia serious adverse events was 0∙15% for 
budesonide and 0∙13% for placebo, resulting in a hazard ratio of 1∙29 (95% CI 0∙53-3∙12), similar to our 
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odds ratio of 1∙10 for budesonide and risk of pneumonia/LRTI. Overall there was no increased risk with 
higher budesonide doses or any difference between budesonide and fluticasone propionate (9), however 
pneumonia was not the primary end point in the trials. 
Although our data show a possible dose response relationship, with higher doses of ICS being associated 
with an increased risk of pneumonia or LRTI the biological mechanism explaining the association 
between risk of infection in asthma and ICS is not clear. There is contradictory evidence on the ability of 
ICS to influence bacterial numbers. Mouse models (13, 14) and in vitro studies of human bronchial 
epithelial cells (15, 16) have demonstrated that ICS reduce bacterial load or invasion, whereas steroid 
treatment can reactivate chronic infection by atypical bacteria, in vitro and in animal models (17, 18). 
People with chronic respiratory disease receiving ICS have also been found to have an increased risk of 
non-tuberculous mycobacterial infection (19, 20) and altered airway microbiota when compared to normal 
subjects (21). Studying the lung microbiota to delineate whether asthma itself or treatment with ICS alters 
the lung microbiome may help answer questions of causation. 
Conclusion 
We have shown that ICS are associated with an increased risk of pneumonia and LRTI in people with 
asthma. Our results suggest that the dose of ICS prescribed should be kept to the minimum necessary 
and that the dose should be stepped down if the patient is well controlled. Furthermore prescribers should 
consider the possibility that infection, rather than underlying asthma, may be driving symptoms before 
increasing the dose of inhaled corticosteroid. This may be important before prescribers increase the ICS 
dose to treat recurrent symptoms. A review and meta-analysis of asthma studies involving ICS and an 
exploration of the effect of ICS on the lung microbiota are now required.  
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Table 1. Demographic data for Cases and Controls 
 Cases N=9059 
N (%) 
Controls n=54189 
N (%) 
Univariate Odds Ratios 
Gender 
Male 
Females 
 
3750 (41.4) 
5309 (58.6) 
 
22394 (41.3) 
31795 (58.7) 
 
Age in years (Mean (SD)) 58.6 (17.2) 58.6 (17.2)  
Smoking status 
Never 
Ex  
Current 
Unknown 
 
3165 (34.9) 
3107 (34.3) 
2315 (25.6) 
472 (5.2) 
 
24125 (44.5) 
15818 (29.2) 
10403 (19.2) 
3853 (7.1) 
 
1.00 
1.51 (1.43 to 1.60) 
1.70 (1.60 to 1.80) 
0.93 (0.84 to 1.04) 
Charlson Index 
0 
1 
2 
3 
4 
>= 5 
 
3414 (37.7) 
3694 (40.8) 
1256 (13.9) 
481 (5.3) 
162 (1.8) 
52 (0.6) 
 
28389 (52.4) 
19157 (35.4) 
4697 (8.7) 
1413 (2.6) 
423 (0.8) 
110 (0.2) 
 
1.00 
1.84 (1.75 to 1.94) 
2.84 (2.63 to 3.08) 
3.77 (3.35 to 4.23) 
4.31 (3.57 to 5.21) 
5.41 (3.87 to 7.57) 
Townsend Score 
1 High 
2 
3 
4 
5 Low 
Unknown 
 
1789 (19.8) 
1744 (19.3) 
1746 (19.3) 
1848 (20.4) 
1511 (16.7) 
421 (4.7) 
 
12562 (23.2) 
11297 (20.9) 
10649 (19.7) 
9811 (18.1) 
6893 (12.7) 
2977 (5.5) 
 
1.00 
1.08 (1.01 to 1.16) 
1.15 (1.07 to 1.230 
1.32 (1.23 to 1.42) 
1.54 (1.43 to 1.66) 
0.99 (0.89 (1.11) 
Influenza Vaccination 
No 
Yes 
 
3857 (42.6) 
5202 (56.4) 
 
26059 (48.1) 
28130 (51.9) 
 
1.00 
1.37 (1.30 to 1.44) 
COPD 
No 
Yes 
 
6857 (75.7) 
2202 (24.3) 
 
46653 (86.1) 
7536 (13.9) 
 
1.00 
2.24 (2.11 to 2.38) 
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Table 2. Study population medication use for cases and controls 
 Cases N=9059 
N (%) 
Controls n=54189 
N (%) 
Univariate Odds Ratios 
Reliever use in the last year 
0 
1-2 
3-6 
7-12 
>=13 
 
2095 (23.1) 
1357 (15.0) 
1617 (17.9) 
1636 (18.1) 
2354 (26.0) 
 
21433 (39.6) 
9790 (18.1) 
8995 (16.6) 
7043 (13.0) 
6928 (12.8) 
 
1.00  
1.44 (1.34 to 1.55) 
1.95 (1.81 to 2.09) 
2.61 (2.43 to 2.81) 
3.96 (3.69 to 4.24) 
Oral steroid courses in the last year 
0 
1 
2-3 
4-8 
>=9 
 
5949 (65.7) 
757 (8.4) 
736 (8.1) 
738 (8.2) 
879 (9.7) 
 
46061 (85.0) 
2418 (4.5) 
2136 (3.9) 
1800 (3.3) 
1774 (3.3) 
 
1.00 
2.45 (2.24 to 2.67) 
2.76 (2.53 to 3.02) 
3.36 (3.07 to 3.68) 
4.20 (3.84 to 4.59) 
Most recent ICS in the last 90 days 
No steroids 
Beclometasone 
Budesonide 
Ciclesonide / Mometasone 
Fluticasone proprionate 
 
3988 (44.0) 
1574 (17.4) 
791 (8.7) 
8 (0.1) 
2698 (29.8) 
 
32662 (60.3) 
9316(17.2) 
3682 (6.8) 
79 (0.2) 
8450 (15.6) 
 
1.00 
1.43 (1.34 to 1.53) 
1.83 (1.68 to 2.00) 
0.85 (0.41 to 1.76) 
2.74 (2.59 to 2.89) 
Inhaled corticosteroids dose (mcg) * 
0 
<200 
200-249 
250-399 
400-499 
500-999 
≥1000 
 
3988 (44.2) 
1581 (17.5) 
802 (8.9) 
785 (8.7) 
246 (2.7) 
1370 (15.2) 
257 (2.9) 
 
32662 (60.3) 
9014 (16.7) 
4019 (7.4) 
3399 (6.3) 
947 (1.8) 
3555 (6.6) 
537 (1.0) 
 
1.00  
1.49 (1.40 to 1.59) 
1.69 (1.56 to 1.84) 
1.99 (1.83 to 2.17) 
2.25 (1.95 to 2.61) 
3.34 (3.10 to 3.59) 
4.23 (3.63 to 4.94) 
*was not able to determine strength in 82 individuals 
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Table 3. Association between dose and type of inhaled corticosteroid use and risk of pneumonia or LRTI  
 OR  95% CI Adjusted 
OR** 
95% CI Adjusted 
OR*** 
95% CI 
Any ICS use in the last 90 days 
No  
Yes 
 
1.00 
2.00 
 
 
1.91 to 2.09 
 
 
1.20 
 
 
1.12 to 1.27 
 
1.00 
1.23 
 
 
1.07 to 1.44 
Inhaled corticosteroids use in the last 90 
days 
No steroids 
Beclometasone 
Budesonide 
Ciclesonide/ Mometasone 
Fluticasone 
 
 
1.00 
1.43 
1.83 
0.85 
2.74 
 
 
 
1.34 to 1.53 
1.68 to 2.00 
0.41 to 1.76 
2.59 to 2.89 
 
 
1.00 
1.05 
1.10 
0.54 
1.48 
 
 
 
0.97 to 1.13 
1.00 to 1.21 
0.26 to 1.14 
1.37 to 1.59 
 
 
1.00 
1.13 
1.13 
- 
1.57 
 
 
 
0.95 to 1.34 
0.87 to 1.47 
- 
1.28 to 1.92 
Inhaled corticosteroids dose (mcg)* 
0 
<200 
200-249 
250-399 
400-499 
500-999 
>1000 
 
1.00 
1.49 
1.69 
1.99 
2.25 
3.34 
4.23 
 
 
1.40 to 1.59 
1.56 to 1.84 
1.83 to 2.17 
1.95 to 2.61 
3.10 to 3.59 
3.63 to 4.94 
 
1.00 
1.06 
1.12 
1.24 
1.16 
1.64 
1.85 
 
 
0.99 to 1.14 
1.02 to 1.23 
1.13 to 1.37 
0.99 to 1.36 
1.50 to 1.80 
1.56 to 2.19 
 
1.00 
1.16 
1.00 
1.44 
1.18 
2.01 
2.52 
 
 
0.98 to 1.38 
0.78 to 1.28 
1.09 to 1.90 
0.67 to 2.06 
1.52 to 2.64 
1.05 to 6.01 
* n=62882 
** adjusted for number of relievers in the last year, Charlson index, smoking, social class, use of oral 
steroids in the last year. 
*** n= 11210; restricted to individuals who were less than 40 years old, did not have a diagnosis of COPD 
or bronchiectasis, did not change their steroid in the previous 90 days and adjusted for number of 
relievers in the last year, Charlson index, smoking, social class, use of oral steroids in the last year. 
(Individuals with Ciclesonide/ Mometasone were excluded from the analyses due to small numbers) 
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Table 4 Analysis combining type of inhaled corticosteroid and dose with risk of pneumonia or LRTI 
ICS use in the last 90 days Cases 
N (%) 
Controls 
N (%) 
Odds 
Ratio 
Adjusted 
Odds 
Ratio ** 
95% CI Adjusted 
Odds Ratio 
*** 
95% CI 
No steroids 
Beclometasone low dose ≤ 200mcg 
Beclometasone high dose > 200mcg 
Budesonide low dose ≤ 200mcg 
Budesonide high dose > 200mcg 
Ciclesonide/ Mometasone ≤ 200mcg 
Ciclesonide/ Mometasone > 200mcg 
Fluticasone low dose ≤ 250mcg 
Fluticasone high dose > 250mcg 
3988 (44.0) 
1293 (14.3) 
281 (3.1) 
568 (6.3) 
223 (2.5) 
6 (0.1) 
2 (0.02) 
1071 (11.8) 
1627 (18.0) 
32662 (60.3) 
8049 (14.9) 
1267 (2.3) 
2824 (5.2) 
858 (1.6) 
56 (0.1) 
23 (0.04) 
4358 (8.0) 
4092 (7.6) 
1.00 
1.36 
1.91 
1.71 
2.25 
0.89 
0.74 
2.10 
3.45 
1.00 
1.02 
1.23 
1.10 
1.12 
0.57 
0.49 
1.29 
1.69 
 
0.95 to 1.11 
1.06 to 1.42 
0.99 to 1.22 
0.95 to 1.33 
0.23 to 1.34 
0.11 to 2.13 
1.18 to 1.41 
1.55 to 1.84 
1.00 
1.12 
1.33 
1.12 
1.29 
 
 
1.31 
2.06 
 
0.94 to 1.33 
0.76 to 2.32 
0.85 to 1.48 
0.72 to 2.31 
 
 
1.03 to 1.67 
1.57 to 2.69 
* n=62882 
** adjusted for number of relievers in the last year, Charlson index, smoking, social class, use of oral 
steroids in the last year 
*** n= 11210; restricted to individuals who were less than 40 years old, did not have a diagnosis of COPD 
or bronchiectasis, did not change their steroid in the previous 90 days and adjusted for number of 
relievers in the last year, Charlson index, smoking, social class, use of oral steroids in the last year. 
(Individuals with Ciclesonide/ Mometasone were excluded from the analyses due to small numbers) 
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Table 5 Restricted analysis of association between type and dose of inhaled corticosteroid in individuals 
who had a prescription for steroids in the last 90 days use and risk of pneumonia or LRTI, with low dose 
beclometasone as control group 
ICS use in the last 90 days OR Adjusted OR** 95% CI Adjusted OR*** 95% CI 
Beclometasone low dose ≤ 200mcg 
Beclometasone high dose > 200mcg 
Budesonide low dose ≤ 200mcg 
Budesonide high dose > 200mcg 
Ciclesonide/ Mometasone low dose ≤ 200mcg 
Ciclesonide/ Mometasone high dose > 200mcg 
Fluticasone low dose ≤ 250mcg 
Fluticasone high dose > 250mcg 
1.00 
1.49 
1.31 
1.89 
0.81 
0.45 
1.59 
2.64 
1.00 
1.29 
1.14 
1.32 
0.66 
0.41 
1.33 
1.78 
 
1.10 to 1.53 
1.00 to 1.29 
1.09 to 1.59 
0.25 to 1.73 
0.09 to 1.83 
1.19 to 1.83 
1.19 to 1.48 
1.00 
1.26 
0.98 
1.67 
 
 
1.38 
2.10 
 
0.59 to 2.68 
0.37 to 1.43 
0.76 to 3.71 
 
 
1.00 to 1.93 
1.44 to 3.07 
* n=17380 
** adjusted for number of relievers in the last year, Charlson index, smoking, social class, use of oral 
steroids in the last year 
***  n=1372; restricted to individuals who were less than 40 years old, did not have a diagnosis of COPD 
or bronchiectasis, did not change their steroid in the previous 90 days and adjusted for number of 
relievers in the last year, Charlson index, smoking, social class, use of oral steroids in the last year. 
(Individuals with Ciclesonide/ Mometasone were excluded from the analyses due to small numbers)  
